2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Profiling, Treatment Considerations, Drug Development, Supportive Care, Biological Therapies, Transplantation, Non-Biological Therapies, Pharmacology, Adverse Events, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Diseases, Immunology, GVHD, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, ALL, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Study Population, Human, Adult, Animal Model
PAPER

4095 Poor mobilization in autologous transplantation of B-ALL patients is associated with delayed engraftment and HSC/MPP-centered graft remodeling

Hongye Gao, MD, Yawei Zheng2, Chenfeina Feng3, Lisha Wang4, Erlie Jiang, MD5, Fang Dong, PhD6
1 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
2 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
3 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
4 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
5 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
6 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China

BACKGROUND

Autologous stem cell transplantation (ASCT) remains an option for patients with B-cell acute lymphoblastic leukemia (B-ALL), but poor hematopoietic stem/progenitor cell (HSPC) mobilization impairs engraftment and remains a major challenge. Acute leukemia is associated with poor mobilization, yet its cellular basis is rarely characterized. We integrated clinical outcomes with single-cell RNA sequencing (scRNA-seq) of B-ALL grafts to define the burden and cellular basis of poor mobilization.

METHODS

The NICHE cohort (NCT04645199) included 228 B-ALL patients undergoing autologous stem cell collection (2004-2024); we assessed CD34+ yield and post-transplant engraftment. Patients were classified as Poor, Standard, or Good by total CD34+ yield/kg (<2, 2-5, >=5 x106, respectively). scRNA-seq of enriched CD34+ cells (119,338 cells, 22 samples; MRD-negative) included healthy bone marrow (n=4), mobilized healthy blood (n=6), B-ALL Good (n=4), Poor (n=4), Standard (n=1), and paired pre-/post-plerixafor specimens from 3 Poor donors. Donors (not cells) were the unit of biological replication for Milo, edgeR pseudobulk, pathway, and pySCENIC analyses (DEGs FDR<=0.05, |log2FC|>=0.5). Engraftment delay was also assessed by 1:1 propensity-score-matched analysis on CD34+ dose. Good and Poor CD34+ cells were xenografted at equal dose into NOG mice (n=3/group; 5.8x104 cells/mouse); peripheral-blood CD45+ chimerism was measured at weeks 4, 8, and 12.

RESULTS

Among 228 B-ALL patients, 44 (19.3%) were Poor, 86 (37.7%) Good, and 98 (43.0%) Standard mobilizers. Collection failure alone precluded ASCT in 9 (3.9%); relapse/MRD did so in 3 (1.3%). Median infused CD34+ dose was lower in Poor than Good mobilizers (1.9 vs 3.8 x106/kg), as was engraftment speed (neutrophil 14.5 vs 12 days; platelet 18 vs 13 days; both P<0.0001). In an exploratory 1:1 matched analysis of equal doses of infused CD34+ cells, Poor mobilizers showed median within-pair engraftment delays of 4.5 days for WBC (28 pairs; P<0.001) and 15.5 days for platelets (24 pairs; P=0.002). After equal-dose CD34+ xenotransplantation into NOG mice, week-4 peripheral-blood CD45+ chimerism was lower in Poor than Good (P=0.019; n=3/group).

HSPC composition did not differ between Good and Poor (PERMANOVA P=0.714; 0/3,140 Milo neighborhoods significant), pointing to functional rather than compositional remodeling. Poor HSC/MPP showed broad pathway remodeling (242 HSC, 179 MPP significant pathways; OXPHOS, MYC-target, E2F-target, mTORC1) covarying with four data-derived E2F1/YBX1 regulon axes, and lower external LT-HSC signature scores than Good HSC (mean difference -0.180; P=0.0286, FDR=0.086).

GMPs from Poor mobilizers instead showed higher OXPHOS, mTORC1, glycolysis, and NF-kB/TNF pathway enrichment. Among 10 evaluable cell types, only CLP and GMP retained Poor-associated genes replicated in both Poor-vs-Good and Poor-vs-HD contrasts, though sparse rather than broad: THSD7A+ GMP were less frequent in Poor (log2FC=-4.812, FDR=0.0042; 2.79% vs 31.98% median donor fraction, exact P=0.0286, FDR=0.057, LOSO-robust), while MS4A1+, B-primed CLP-like cells were more frequent (13.46% vs 1.88%; P=0.0286).

This THSD7A-low GMP state was externally supported: in GSE223972 (MM), plerixafor mobilization increased THSD7A+ GMP frequency versus G-CSF alone (9.44% vs 5.73%), and GSE285943 reproduced this multigene state in myeloid-enriched HSPCs.

In 3 B-ALL patients paired before/after plerixafor, pooled-HSPC pseudobulk GSEA showed attenuated TNF-NF-kB signaling and leukocyte adhesion regardless of response (FDR 1.71x10-11 to 2.41x10-7; concordant in all 3). The two responders showed concordant decreases across HSC/MPP regulon-pathway axes, with expansion of THSD7A+ GMPs, increased CD34+ counts, and contraction of MS4A1+ CLPs, whereas the non-responder showed discordant, non-restorative shifts across the same axes.

CONCLUSIONS

Poor mobilization affected ~20% of B-ALL patients undergoing ASCT with delayed engraftment. Poor HSC/MPP displayed coordinated metabolic and transcriptional remodeling and exploratory evidence of reduced primitive-state scores, consistent with post-transplant functional deterioration. Reduced THSD7A+ GMP frequency, external cross-dataset support, and expansion after plerixafor in responders nominate it as a hypothesis-generating marker for poor mobilizers and plerixafor response, warranting independent validation.

Hongye Gao, MD: No relevant conflicts of interest to declare.